<DOC>
	<DOC>NCT01091649</DOC>
	<brief_summary>The objective of this study is to assess the relative bioavailability of two test tablet formulations of ABT-450 as compared to the ABT-450 hard gelatin capsule formulation as a reference.</brief_summary>
	<brief_title>Study in Healthy Adults to Evaluate the Bioavailability of Two Test Tablet Formulations of ABT-450</brief_title>
	<detailed_description>This is a two part study. Part 1 is a single dose, three period, complete crossover study in approximately 21 subjects. Part 2 is a single dose, two period, complete crossover study in approximately 20 subjects.</detailed_description>
	<mesh_term>Ritonavir</mesh_term>
	<criteria>Inclusion Criteria Overall healthy subjects Nonchildbearing potential females included Exclusion Criteria Positive test for HAV IgM, HBsAg, antiHCV Ab or antiHIV Ab Clinically significant cardiovascular, respiratory (except mild asthma), renal, gastrointestinal, hematologic, neurologic, thyroid, or any uncontrolled medical illness or psychiatric disorder Use of tobacco or nicotinecontaining products with the 6month period prior to study drug administration Abnormal screening laboratory results that are considered clinically significant by the investigator Pregnant or breastfeeding female; requirement for any OTC and/or prescription medication, vitamins and/or herbal supplements on a regular basis Previous exposure to ABT450</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>Pharmacokinetics, Safety</keyword>
</DOC>